Edgar Filing: ENANTA PHARMACEUTICALS INC

Date: October 1, 2014

ENANTA PHARMACEUTICALS, INC.

/s/ Paul J. Mellett

Paul J. Mellett

Chief Financial Officer

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2014

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35839

04-3205099

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

(617) 607-0800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.02 Termination of a Material Definitive Agreement.

On September 30, 2014, Enanta Pharmaceuticals and Novartis Institutes for Biomedical Research entered into an amendment to their Collaboration and License Agreement entered into effective as of February 16, 2012, as amended, in light of Novartis’ determination that hepatitis C is no longer a strategic focus of Novartis. The amendment provides for termination of the collaboration and transition of EDP-239 and the other NS5A inhibitor compounds developed under the collaboration back to Enanta, as well as completion or transition of specified proof-of-concept clinical studies currently underway involving EDP-239, and a combination study with EDP-239 and Alisporivir, a cyclophilin inhibitor licensed by Novartis from Debiopharm. The amendment also includes an option for Enanta to purchase from Novartis any unused API and drug product related to EDP-239.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.